Abstract Details

Title Longitudinal Assessment of Optical Coherence Tomography in Patients with Relapsing-Remitting Multiple Sclerosis on Three Disease Modifying Therapies

Topic Multiple Sclerosis

Presentation(s) P7 - Poster Session 7 (5:30 PM-6:30 PM)

Poster/Presentation
Number 9-020

Objective To perform a longitudinal analysis of optical coherence tomography (OCT) and clinical disease progression in patients with relapsing-remitting multiple sclerosis (RRMS) on three disease-modifying therapies: dimethyl fumarate (DMF), Interferon beta-1a (IFNβ-1a), and Natalizumab.

Background

Degeneration of the retinal layer over time occurs with MS, but the effects can be mitigated by DMTs. DMF, IFNβ-1a, and Natalizumab are DMTs for RRMS and may slow the progression of neuroaxonal loss. OCT is a sensitive method in detecting retinal nerve degeneration and quantifying potential neuroprotective effects with different DMTs.

Design/Methods Retrospective analysis was performed on 60 RRMS patients, 20 in each group on 24months of continuous treatment with DMF, IFNβ-1a, or Natalizumab. Patients with baseline and 24-month EDSS scores, visual acuity, timed 25-foot walk (T25FW), retinal nerve fiber layer (RNFL) thickness, total macular volume (TMV), and clinical brain and spinal cord MRIs were included.

Results Demographics were: DMF group 65% female, mean age 49; IFNβ-1a group 75% female, mean age 58; and Natalizumab group 65% female, mean age 44. In DMF group from baseline to 24 months, RNFL thickness (85.9 μm to 86.1 μm; p=0.79) and TMV (8.3 mm³ to 8.3 mm³; p=0.91). In IFNβ-1a group, RNFL thickness (84.5 μm to 84.0 μm; p=0.81), and TMV (8.3 mm³ to 8.2 mm³; p=0.81). In Natalizumab group, RNFL thickness (86.5 μm to 85.9 μm; p=0.61), and TMV (8.4 mm³ to 8.4 mm³; p=0.91). During the observational period, EDSS, visual acuity, and T25FW amongst all three groups remain unchanged and none of the patients experienced a clinical relapse. Only 4 new lesions over 24 months in all three groups were observed on the clinical brain and spinal cord MRIs (n=120).

Conclusions In this longitudinal study, all DMT groups demonstrate stability in OCTs, clinical, and radiological measures in over 24 months. Inhibition of neurodegeneration processes may be achieved with the therapies.

Authors/Disclosures
Ka-Ho Wong (U of U Neurology Clinic) PRESENTER	The institution of Mr. Wong has received research support from The Sumaira Foundation . The institution of Mr. Wong has received research support from The Siegel Rare Neuroimmune Association.
Rae E. Bacharach, DO (Penn State University, Milton S Hershey Medical Center)	Dr. Bacharach has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for �鶹��ýӳ��.
Julia Klein, NP (University of Utah School of Medicine)	An immediate family member of Ms. Klein has received personal compensation for serving as an employee of Amgen. An immediate family member of Ms. Klein has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen.
M. M. Paz Soldan, MD, PhD (Mayo Clinic)	Dr. Paz Soldan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. The institution of Dr. Paz Soldan has received research support from National Institutes of Health. The institution of Dr. Paz Soldan has received research support from National Multiple Sclerosis Society. The institution of Dr. Paz Soldan has received research support from Western Institute for Biomedical Research. The institution of Dr. Paz Soldan has received research support from Biogen. The institution of Dr. Paz Soldan has received research support from Novartis. The institution of Dr. Paz Soldan has received research support from Clene Nanomedicine.
John W. Rose, MD, F�鶹��ýӳ�� (Imaging and Neurosciences Center)	The institution of Dr. Rose has received research support from National Multiple Sclerosis Society. The institution of Dr. Rose has received research support from Guthy Jackson Charitable Foundation. The institution of Dr. Rose has received research support from NIH . The institution of Dr. Rose has received research support from VA. The institution of Dr. Rose has received research support from Biogen. The institution of Dr. Rose has received research support from Friends of MS. Dr. Rose has received intellectual property interests from a discovery or technology relating to health care.

�鶹��ýӳ��

�鶹��ýӳ��